Stockreport

Invivyd: Maintaining Hold Rating With VYD2311 Alternative To Covid-19 Vaccination [Seeking Alpha]

Invivyd, Inc.  (IVVD) 
PDF VYD2311 offers broader patient coverage and intramuscular dosing, with phase 3 DECLARATION and LIBERTY trials set to begin by end of 2025; Topline data mid-2026. Comp [Read more]